(AdSS, which adjusts the RTSS for rescue medication use) and daily individual rhinoconjunctivitis symptom scores. The primary efficacy endpoint, the daily CS during the pollen period while on treatment, was analyzed using a repeated measures ANCOVA model, as were the above secondary efficacy endpoints. The safety of the treatment was documented by means of adverse event reporting, laboratory data and physical examination findings. Results: The 300IR group showed a relative improvement in daily CS versus placebo of -28.2% (relative difference in LS Means, 95%, CI [-43.4%; -13.0%], P ¼ 0.0003). Significant improvements in RTSS and AdSS were consistent with previous European studies. There were also significant improvements in the individual symptoms: sneezing, rhinorrhea, nasal congestion, itchy eyes and watery eyes. The 300IR SLIT tablet was generally well tolerated. The most commonly reported treatment-emergent adverse events (TEAEs) in the 300IR group were application site-reactions: oral pruritus, throat irritation, and nasopharyngitis. No drug-related serious TEAEs were reported. The overall safety profile of 300 IR SLIT tablet was consistent with that observed in European studies. Conclusions: The 300IR SLIT tablet showed clinically meaningful efficacy, with significant improvements on the primary and secondary endpoints. The treatment was well-tolerated. Overall, the results in United States are consistent with European observations. Background: Oral and sublingual immunotherapy to food allergens aim to enable the safe consumption of the foods containing these allergens. Methods: Systematic review of intervention studies, searching 11 international databases and contacting an international panel of experts. Studies were critically appraised using the Cochrane approach and meta-analysed. Results: We identified 721 potentially relevant papers, from which we selected 16 reports of 14 eligible trials (12 randomised controlled trials and 2 controlled clinical trials). Eleven of these trials evaluated oral immunotherapy and the remaining 3 investigated sublingual immunotherapy.Meta-analysis revealed that immunotherapy substantially reduced the average risk of persisting food allergy in patients (RR ¼ 0.24; 95% CI, 0.11-0.50). Pooling of the safety data however revealed an increased average risk of systemic adverse reactions in those receiving immunotherapy (RR ¼ 1.13; 95% CI, 1.00-1.27); the average risk of local (minor oropharyngeal/gastro-intestinal) adverse reactions was also increased in those receiving immunotherapy (RR ¼ 1.16; 95% CI, 1.04, 1.30). Meta-analysis of immunological data demonstrated that allergen skin prick test wheal diameter significantly decreased in experimental groups compared to controls (mean difference -2.96 mm; 95% CI, -4.48, -1.45), whilst specific-IgG4 increased by an average of 19.9 mg/ mL (95% CI, 17.1, 22.6); however there was no change in specific IgE: -5.2 kU/L (95% CI, -12.39, 1.99). Conclusions: Oral/sublingual immunotherapy substantially reduces the risk of food allergy, this effect being mediated by immunological mechanisms. However, because of the stringent exclusion criteria used in many of the reviewed studies and the increased risk of systemic adverse events, immunotherapy cannot yet be recommended for routine clinical practice. Future research needs to focus on larger randomised controlled trials investigating long-term clinical tolerance induction, impact on quality of life and estimating the cost-effectiveness of treatment. Overall, this appears to be a promising line of potentially disease-modifying treatment for people with a range of IgE-mediated food allergies. Background: Management of hereditary angioedema (HAE) comprises the prophylaxis and emergency treatment of edematous attacks. Our aim was to appraise the wide variety of the prophylactic use of plasma-derived human C1-inhibitor concentrate in HAE type I and type II patients. Methods: 125 patients with HAE (54 males, 71 females) were included in our study. Classical short-term prophylaxis (STP) was administered before surgical or diagnostic interventions in the head and neck region and other types of major surgery, as well as before endotracheal intubation. Alternatively, STP was introduced before the expected and unavoidable onset of triggering factors.
Background: Oral and sublingual immunotherapy to food allergens aim to enable the safe consumption of the foods containing these allergens. Methods: Systematic review of intervention studies, searching 11 international databases and contacting an international panel of experts. Studies were critically appraised using the Cochrane approach and meta-analysed. Results: We identified 721 potentially relevant papers, from which we selected 16 reports of 14 eligible trials (12 randomised controlled trials and 2 controlled clinical trials). Eleven of these trials evaluated oral immunotherapy and the remaining 3 investigated sublingual immunotherapy.Meta-analysis revealed that immunotherapy substantially reduced the average risk of persisting food allergy in patients (RR ¼ 0.24; 95% CI, 0.11-0.50). Pooling of the safety data however revealed an increased average risk of systemic adverse reactions in those receiving immunotherapy (RR ¼ 1.13; 95% CI, 1.00-1.27); the average risk of local (minor oropharyngeal/gastro-intestinal) adverse reactions was also increased in those receiving immunotherapy (RR ¼ 1.16; 95% CI, 1.04, 1.30). Meta-analysis of immunological data demonstrated that allergen skin prick test wheal diameter significantly decreased in experimental groups compared to controls (mean difference -2.96 mm; 95% CI, -4.48, -1.45), whilst specific-IgG4 increased by an average of 19.9 mg/ mL (95% CI, 17.1, 22.6); however there was no change in specific IgE: -5.2 kU/L (95% CI, -12.39, 1.99). Conclusions: Oral/sublingual immunotherapy substantially reduces the risk of food allergy, this effect being mediated by immunological mechanisms. However, because of the stringent exclusion criteria used in many of the reviewed studies and the increased risk of systemic adverse events, immunotherapy cannot yet be recommended for routine clinical practice. Future research needs to focus on larger randomised controlled trials investigating long-term clinical tolerance induction, impact on quality of life and estimating the cost-effectiveness of treatment. Overall, this appears to be a promising line of potentially disease-modifying treatment for people with a range of IgE-mediated food allergies. Background: Management of hereditary angioedema (HAE) comprises the prophylaxis and emergency treatment of edematous attacks. Our aim was to appraise the wide variety of the prophylactic use of plasma-derived human C1-inhibitor concentrate in HAE type I and type II patients. Methods: 125 patients with HAE (54 males, 71 females) were included in our study. Classical short-term prophylaxis (STP) was administered before surgical or diagnostic interventions in the head and neck region and other types of major surgery, as well as before endotracheal intubation. Alternatively, STP was introduced before the expected and unavoidable onset of triggering factors. Results: Before diagnosis of HAE, 128 interventions performed on 43 out of 125 patients induced edema: dental procedures (99 interventions in forty patients), ENT interventions (13/9 patients), surgery in the head and neck region (2/2 patients), surgery under general anesthesia (3/3 patients), gastroduodenoscopy (2/2 patients), delivery (6/6 patients) and artificial abortion (3/ 2 patients). After diagnosis of HAE, 500 IU of C1-INH concentrate was administered for STP, one hour before dental intervention (to 14 patients in 26 cases), surgery on the head or neck (to 7 patients in 7 cases), surgery under ETN (to 11 patients in 12 cases), diagnostic procedures (1 colonoscopy, 2 bronchoscopy, 4 gastroduodenoscopy, 1 cardiovascular catheterization), artificial abortion (to 4 patients in 6 cases), or childbirth (to 11 patients in 11 cases). Thirty-three of the 125 patients received prophylactic treatment on 70 occasions altogether. The medical history was positive for oedema provoked by medical interventions in 20 of the 33 patients undergoing STP with C1-INH concentrate. Eight patients received alternative prophylaxis: 2 patients during airway infections, 5 others before stressful life events, and one patient on the first day of the menstrual cycle over 4 months. In all cases, C1-INH concentrate prevented the occurrence of attacks. Conclusions: STP with C1-INH concentrate was effective in preventing angioedematous attacks in all cases. After interventions, during 48 hours observation period, edematous attacks did not occur. Repeated administration did not diminish its efficacy. C1-INH concentrate was well tolerated, and it was never associated with potentially treatment-related adverse effects. 
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